Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with paclitaxel and carboplatin in stage IVB, recurrent or persistent cervical cancer (JGOG1079)
jRCTs051180157Phase 2Completed
- Sponsor
- Japanese Gynecologic Oncology Group
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in Cervical Cancer (CC), sponsored by Japanese Gynecologic Oncology Group. Primary endpoint: Progression-free survival. Started Mar 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCTs051180157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180157.